AB Science completes EUR 14.2 million capital increase to support clinical development and strengthen financial position
Executive summary: AB Science completed a capital increase of EUR 14.2 million in gross proceeds on August 10, 2026, as announced via GlobeNewswire. The financing strengthens the company’s balance sheet to support ongoing clinical trials, particularly for masitinib in ALS and cancer, following a strategic focus on two priority programs announced in July 2026.
Who is involved: AB Science (company), investors participating in the capital increase, and GlobeNewswire as the disseminating source.
Likely next: Proceeds will be allocated to clinical development; next updates expected on trial progress for masitinib in upcoming quarters, with potential regulatory milestones in 2027.
AB Science announced the successful completion of a capital increase totaling EUR 14.2 million in gross proceeds, completed on August 10, 2026. The funds are intended to advance its clinical programs, particularly those focused on masitinib in neurodegenerative and oncological indications. This financing follows a strategic update from July 2026 where the company prioritized two core clinical programs by suspending non-essential trials. The capital raise reflects investor confidence in AB Science’s focused R&D strategy amid ongoing clinical development efforts.
Timeline
- — AB Science announces today the successful completion of capital increases of a total gross amount of EUR 14.2 million (GlobeNewswire)
- — AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs (GlobeNewswire)
Analysis — what this means
Likely next events
- AB Science to provide clinical update on masitinib in ALS by Q4 2026
- Potential interim data readout from Phase 3 pancreatic cancer trial in H1 2027
- Use of proceeds disclosure expected in next financial report (Q3 2026)
Sectors affected
- Biotechnology
- Pharmaceutical R&D
- Oncology therapeutics
- Neurology drug development
Regulatory implications
- Funds support ongoing clinical trials subject to EMA and FDA oversight
- No change in regulatory status; trial continuance depends on safety and efficacy data
- Capital increase does not trigger special regulatory filings beyond standard disclosure
Historical parallels
- Similar capital raise by Ipsen in 2021 (EUR 150M) to fund palovarotene development
- AB Science’s 2020 rights issue (EUR 10M) to support early-stage clinical work
- 2019 capital increase by Nanobiotix (EUR 20M) for NBTXR3 clinical advancement
Key entities
Sources
- AB Science announces today the successful completion of capital increases of a total gross amount of EUR 14.2 million — GlobeNewswire
- AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs — GlobeNewswire